Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesVinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma
Cancer, 06/25/09
Vaughn DJ et al. - In a study to evaluate the activity and safety of vinflunine in pts with locally advanced or metastatic urothelial carcinoma (UC) who developed disease progression within 12 mos of platinum-containing chemotherapy, it was shown that vinflunine demonstrates moderate activity in pts with platinum-pretreated UC. Toxicity is manageable and noncumulative.
Methods- Pts with UC were eligible if they received a prior platinum-based regimen in the neoadjuvant/adjuvant setting or as first-line treatment for advanced/metastatic disease and had developed disease progression within 12 mos.
- Vinflunine was administered intravenously every 3 wks.
- Pts with Karnofsky performance status of 80 or 90, impaired renal function, prior pelvic irradiation, or age 75 yrs received an initial dose of 280 mg/m2, which was escalated to 320 mg/m2 in cycle 2 if well tolerated.
- All other pts received an initial dose of 320 mg/m2.
- Primary endpoint was response rate.
- 22 pts achieved a partial response, with a response rate of 15% with a median duration of response of 6.0 mos.
- 64 (42%) pts had stable disease.
- Median progression-free survival was 2.8 mos, and median overall survival was 8.2 mos.
- Myelosuppression was the most frequent adverse event, with grade 3 of 4 neutropenia reported in 58% of pts.
- Grade 3 of 4 febrile neutropenia occurred in 10 (7%) pts.
- Nonhematologic treatment-related events (grade 3 of 4) were generally manageable and included constipation (17%), asthenia/fatigue (13%), ileus (5%), and abdominal pain (5%).
Today in Bladder...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/26/09
Fesoterodine: a new antimuscarinic for overactive bladder
Aging Health, 10/13/09
Frequently asked questions in the evaluation and management of overactive bladder
The Journal of Family Practice, 11/02/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/14/09
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Annals of Oncology, 10/16/09
Article Search
Sponsor